These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 2619946)

  • 1. Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma.
    West WH; Tauer KW; Yannelli JR; Marshall GD; Orr D; Lewis M; Birch R; Oldham RK
    Mol Biother; 1989; 1(5):268-74. PubMed ID: 2619946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
    West WH; Tauer KW; Yannelli JR; Marshall GD; Orr DW; Thurman GB; Oldham RK
    N Engl J Med; 1987 Apr; 316(15):898-905. PubMed ID: 3493433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.
    Geertsen PF; Hermann GG; von der Maase H; Steven K
    J Clin Oncol; 1992 May; 10(5):753-9. PubMed ID: 1569448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 therapy in relapsed acute myelogenous leukemia.
    Meloni G; Vignetti M; Pogliani E; Invernizzi R; Allione B; Mirto S; Sica S; Leoni F; Selleri C; Mandelli F
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S43-7. PubMed ID: 9457393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
    Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical application of continuous infusion of recombinant interleukin-2.
    West WH
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in biochemical laboratory investigation in patients treated with constant infusion recombinant interleukin-2.
    Ubhi SS; Horsburgh T; Veitch PS; Bell PR
    Anticancer Res; 1991; 11(6):2059-62. PubMed ID: 1776840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
    Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 therapy for refractory and relapsing lymphomas.
    Tourani JM; Levy V; Briere J; Levy R; Franks C; Andrieu JM
    Eur J Cancer; 1991; 27(12):1676-80. PubMed ID: 1782082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
    Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
    Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
    Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT
    N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2.
    Gore ME; Galligioni E; Keen CW; Sorio R; Loriaux EM; Grobben HC; Franks CR
    Eur J Cancer; 1994; 30A(3):329-33. PubMed ID: 8204354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
    Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.
    von der Maase H; Geertsen P; Thatcher N; Jasmin C; Mercatello A; Fosså SD; Symann M; Stoter G; Nagel G; Israel L
    Eur J Cancer; 1991; 27(12):1583-9. PubMed ID: 1782066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
    Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M
    Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.